688488 艾迪药业
已收盘 05-21 15:00:01
资讯
新帖
简况
艾迪药业（688488）披露变更保荐机构后重新签订募集资金专户存储三方监管协议的公告，5月21日股价下跌1.25%
证券之星 · 17:49
艾迪药业（688488）披露变更保荐机构后重新签订募集资金专户存储三方监管协议的公告，5月21日股价下跌1.25%
股市必读：艾迪药业(688488)股东户数1.17万户，较上期增加7.33%
证券之星 · 05-06
股市必读：艾迪药业(688488)股东户数1.17万户，较上期增加7.33%
华鑫证券：首次覆盖艾迪药业给予买入评级
证券之星 · 05-05
华鑫证券：首次覆盖艾迪药业给予买入评级
每周股票复盘：艾迪药业（688488）股东户数增7.33%，净利降51.19%
证券之星 · 05-02
每周股票复盘：艾迪药业（688488）股东户数增7.33%，净利降51.19%
图解艾迪药业一季报：第一季度单季净利润同比下降51.19%
证券之星 · 04-29
图解艾迪药业一季报：第一季度单季净利润同比下降51.19%
4月15日艾迪药业涨5.56%，兴全合兴LOF基金重仓该股
证券之星 · 04-15
4月15日艾迪药业涨5.56%，兴全合兴LOF基金重仓该股
每周股票复盘：艾迪药业（688488）ACC085注射液获临床试验批准
证券之星 · 04-12
每周股票复盘：艾迪药业（688488）ACC085注射液获临床试验批准
艾迪药业（688488）披露ACC085注射液获临床试验批准通知书，4月7日股价下跌0.81%
中金财经 · 04-07
艾迪药业（688488）披露ACC085注射液获临床试验批准通知书，4月7日股价下跌0.81%
艾迪药业最新公告：ACC085注射液获药物临床试验批准
证券之星 · 04-06
艾迪药业最新公告：ACC085注射液获药物临床试验批准
每周股票复盘：艾迪药业（688488）周内股价大涨15%登龙虎榜
证券之星 · 04-05
每周股票复盘：艾迪药业（688488）周内股价大涨15%登龙虎榜
艾迪药业：3月31日董事傅和亮增持股份合计13.35万股
证券之星 · 04-01
艾迪药业：3月31日董事傅和亮增持股份合计13.35万股
4月1日艾迪药业（688488）龙虎榜数据：机构净买入3066.93万元，北向资金净买入1217.41万元
证券之星 · 04-01
4月1日艾迪药业（688488）龙虎榜数据：机构净买入3066.93万元，北向资金净买入1217.41万元
图解艾迪药业年报：第四季度单季净利润同比增长84.19%
证券之星 · 03-31
图解艾迪药业年报：第四季度单季净利润同比增长84.19%
每周股票复盘：艾迪药业（688488）拟13,005.9540万元收购南大药业22.2324%股权
证券之星 · 03-29
每周股票复盘：艾迪药业（688488）拟13,005.9540万元收购南大药业22.2324%股权
艾迪药业（688488）披露收购控股子公司少数股东股权进展公告，3月27日股价上涨4.98%
证券之星 · 03-27
艾迪药业（688488）披露收购控股子公司少数股东股权进展公告，3月27日股价上涨4.98%
艾迪药业最新公告：用于治疗HIV感染的多替拉韦钠片获得药品注册批准
中金财经 · 03-15
艾迪药业最新公告：用于治疗HIV感染的多替拉韦钠片获得药品注册批准
艾迪药业：整合酶抑制剂已成为全球抗艾主流治疗方案之一
证券日报 · 03-13
艾迪药业：整合酶抑制剂已成为全球抗艾主流治疗方案之一
艾迪药业定增扩围背后的两难：填补巨亏窟窿，能否赌出一个未来？
新浪证券 · 03-12
艾迪药业定增扩围背后的两难：填补巨亏窟窿，能否赌出一个未来？
艾迪药业：3月9日高管傅和亮增持股份合计6.88万股
证券之星 · 03-09
艾迪药业：3月9日高管傅和亮增持股份合计6.88万股
艾迪药业：3月5日高管傅和亮增持股份合计5.31万股
证券之星 · 03-06
艾迪药业：3月5日高管傅和亮增持股份合计5.31万股
加载更多
公司概况
公司名称：
江苏艾迪药业集团股份有限公司
所属行业：
其他制造业
上市日期：
2020-07-20
主营业务：
江苏艾迪药业集团股份有限公司的主营业务是抗HIV药物和人源蛋白领域药物的研发、生产及销售。公司的主要产品是乌司他丁粗品、其他人源蛋白粗品、HIV新药(艾诺韦林片)、HIV新药(艾诺米替片)、番泻叶颗粒、蜡样芽孢杆菌片、HIV诊断试剂、药品（尿激酶针剂）、低分子量肝素钠及其他。
发行价格：
13.99
{"stockData":{"symbol":"688488","market":"SH","secType":"STK","nameCN":"艾迪药业","latestPrice":15.77,"timestamp":1779346801000,"preClose":15.97,"halted":0,"volume":8065125,"delay":0,"changeRate":-0.0125,"floatShares":421000000,"shares":421000000,"eps":-0.0654,"marketStatus":"已收盘","change":-0.2,"latestTime":"05-21 15:00:01","open":16.08,"high":16.62,"low":15.76,"amount":131000000,"amplitude":0.0539,"askPrice":15.79,"askSize":12,"bidPrice":15.77,"bidSize":159,"shortable":0,"etf":0,"ttmEps":-0.0654,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779413400000},"marketStatusCode":5,"adr":0,"adjPreClose":15.97,"symbolType":"stock_kcb","openAndCloseTimeList":[[1779327000000,1779334200000],[1779339600000,1779346800000]],"highLimit":17.57,"lowLimit":14.37,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":420782808,"isCdr":false,"pbRate":6.81,"roa":"--","roe":"0.78%","epsLYR":-0.05,"committee":-0.089397,"marketValue":6636000000,"turnoverRate":0.0192,"status":1,"afterMarket":{"amount":0,"volume":0,"close":15.77,"buyVolume":0,"sellVolume":0,"time":1779348837558,"indexStatus":"已收盘 05-21 15:30:00","preClose":15.97},"floatMarketCap":6636000000},"requestUrl":"/m/hq/s/688488","defaultTab":"news","newsList":[{"id":"2637831384","title":"艾迪药业（688488）披露变更保荐机构后重新签订募集资金专户存储三方监管协议的公告，5月21日股价下跌1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637831384","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637831384?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:49","pubTimestamp":1779356994,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，艾迪药业报收于15.77元，较前一交易日下跌1.25%，最新总市值为66.36亿元。近日，艾迪药业发布《关于变更保荐机构后重新签订募集资金专户存储三方监管协议的公告》。公司与原保荐机构及银行签订的《募集资金三方监管协议》相应终止，现与国联民生承销保荐及多家银行重新签订了《募集资金专户存储三方监管协议》。本次涉及变更的募集资金专户共8个，部分账户已完成协议重签，其余正在办理中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100033420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633923037","title":"股市必读：艾迪药业(688488)股东户数1.17万户，较上期增加7.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633923037","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633923037?lang=zh_cn&edition=full","pubTime":"2026-05-06 03:39","pubTimestamp":1778009950,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，艾迪药业报收于17.26元，下跌0.23%，换手率2.6%，成交量10.93万手，成交额1.88亿元。来自股本股东变化：截至2026年3月31日，艾迪药业股东户数环比增长7.33%，户均持股数量降至3.6万股。股本股东变化股东户数变动截至2026年3月31日，公司股东户数为1.17万户，较2月28日增加799.0户，增幅为7.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600003188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633918388","title":"华鑫证券：首次覆盖艾迪药业给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2633918388","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633918388?lang=zh_cn&edition=full","pubTime":"2026-05-05 16:25","pubTimestamp":1777969531,"startTime":"0","endTime":"0","summary":"华鑫证券有限责任公司胡博新,吴景欢近期对艾迪药业进行研究并发布了研究报告《公司事件点评报告：抗HIV药物高速增长，创新药研发和国际化布局加快》，首次覆盖艾迪药业给予买入评级。2025年南大药业实现净利润6070.09万元，有效增厚现有业绩和利润。数据显示，全球现存HIV感染者4080万，其中2024年新发感染130万人。首次覆盖，给予“买入”投资评级。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050500004463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632588647","title":"每周股票复盘：艾迪药业（688488）股东户数增7.33%，净利降51.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632588647","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632588647?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:10","pubTimestamp":1777666223,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，艾迪药业报收于17.26元，较上周的17.69元下跌2.43%。本周，艾迪药业4月27日盘中最高价报18.15元。股本股东变化截至2026年3月31日，艾迪药业股东户数为1.17万户，较2月28日增加799户，增幅7.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631024515","title":"图解艾迪药业一季报：第一季度单季净利润同比下降51.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631024515","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631024515?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:52","pubTimestamp":1777463562,"startTime":"0","endTime":"0","summary":"证券之星消息，艾迪药业2026年一季报显示，一季度公司主营收入1.78亿元，同比下降10.03%；归母净利润760.63万元，同比下降51.19%；扣非净利润857.4万元，同比上升15.87%；负债率47.08%，投资收益-18.86万元，财务费用398.13万元，毛利率67.52%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900060890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627404796","title":"4月15日艾迪药业涨5.56%，兴全合兴LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627404796","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627404796?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:10","pubTimestamp":1776240607,"startTime":"0","endTime":"0","summary":"证券之星消息，4月15日艾迪药业涨5.56%，收盘报20.51元，换手率5.65%，成交量23.76万手，成交额4.68亿元。重仓艾迪药业的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为兴证全球基金的兴全合兴LOF。兴全合兴LOF目前规模为30.32亿元，最新净值0.8661，较上一交易日上涨0.36%，近一年上涨43.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500028542.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488","163418"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626112210","title":"每周股票复盘：艾迪药业（688488）ACC085注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626112210","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626112210?lang=zh_cn&edition=full","pubTime":"2026-04-12 02:06","pubTimestamp":1775930773,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘，艾迪药业报收于18.48元，较上周的18.43元上涨0.27%。本周，艾迪药业4月7日盘中最高价报19.68元。艾迪药业当前最新总市值77.76亿元，在生物制品板块市值排名34/51，在两市A股市值排名2434/5196。ACC085为全新化学结构的HIV-1衣壳功能抑制剂，临床前研究显示其对多种HIV-1病毒株及耐药株具有良好的抗病毒活性，并具备长效潜力。公司后续将推进临床试验工作，产品上市尚需进一步审评审批，且对公司近期业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625931146","title":"艾迪药业（688488）披露ACC085注射液获临床试验批准通知书，4月7日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625931146","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625931146?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:07","pubTimestamp":1775556431,"startTime":"0","endTime":"0","summary":"艾迪药业于近日披露《关于ACC085注射液获得药物临床试验批准通知书的自愿性披露公告》。公告显示，江苏艾迪药业集团股份有限公司及全资子公司泸州艾迪医药技术有限公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司自主研发的1类新药ACC085注射液开展用于HIV-1感染风险人群暴露前预防的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260407/32128552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625762005","title":"艾迪药业最新公告：ACC085注射液获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2625762005","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625762005?lang=zh_cn&edition=full","pubTime":"2026-04-06 16:20","pubTimestamp":1775463649,"startTime":"0","endTime":"0","summary":"艾迪药业公告称，公司及全资子公司近日收到国家药监局核准签发的《药物临床试验批准通知书》，同意公司抗艾滋病领域在研1类新药ACC085注射液开展临床试验。ACC085是公司自主研发的全新化学结构的HIV-1衣壳功能抑制剂，临床前研究显示其具有良好的抗病毒活性及长效潜力。公司表示，该事项对近期业绩不会产生重大影响，后续尚需开展临床试验并经审评审批通过后方可生产上市，存在市场竞争、政策变化等风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040600001941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625261647","title":"每周股票复盘：艾迪药业（688488）周内股价大涨15%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2625261647","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625261647?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:15","pubTimestamp":1775326513,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，艾迪药业报收于18.43元，较上周的16.02元上涨15.04%。本周，艾迪药业4月3日盘中最高价报18.84元。本周关注点来自交易信息汇总：艾迪药业因日收盘价涨幅达15%登上龙虎榜。交易信息汇总沪深交易所2026年4月1日公布的交易公开信息显示，艾迪药业因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624513696","title":"艾迪药业：3月31日董事傅和亮增持股份合计13.35万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624513696","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624513696?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:01","pubTimestamp":1775044864,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月1日市场公开信息、上市公司公告及交易所披露数据整理，艾迪药业最新董监高及相关人员股份变动情况：2026年3月31日公司董事,核心技术人员傅和亮共增持公司股份13.35万股，占公司总股本为0.0317%。变动期间公司股价下跌4.26%，3月31日当日收盘报14.85元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100038917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624599492","title":"4月1日艾迪药业（688488）龙虎榜数据：机构净买入3066.93万元，北向资金净买入1217.41万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624599492","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624599492?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:21","pubTimestamp":1775035272,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月1日公布的交易公开信息显示，艾迪药业因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月1日收盘，艾迪药业报收于17.82元，上涨20.0%，换手率6.8%，成交量28.62万手，成交额4.85亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入3066.93万元，北向资金合计净买入1217.41万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623323265","title":"图解艾迪药业年报：第四季度单季净利润同比增长84.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623323265","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623323265?lang=zh_cn&edition=full","pubTime":"2026-03-31 02:29","pubTimestamp":1774895383,"startTime":"0","endTime":"0","summary":"证券之星消息，艾迪药业2025年年报显示，当年度公司主营收入7.19亿元，同比上升72.13%；归母净利润-1953.23万元，同比上升86.17%；扣非净利润-2059.66万元，同比上升86.13%；其中2025年第四季度，公司单季度主营收入1.67亿元，同比上升40.23%；单季度归母净利润-1269.18万元，同比上升84.19%；单季度扣非净利润-198.44万元，同比上升96.94%；负债率43.89%，投资收益-73.63万元，财务费用1371.87万元，毛利率66.79%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033100005632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623333805","title":"每周股票复盘：艾迪药业（688488）拟13,005.9540万元收购南大药业22.2324%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2623333805","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623333805?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:53","pubTimestamp":1774727587,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，艾迪药业报收于16.02元，较上周的15.55元上涨3.02%。本周，艾迪药业3月27日盘中最高价报16.17元。3月23日盘中最低价报14.4元。艾迪药业当前最新总市值67.41亿元，在生物制品板块市值排名36/51，在两市A股市值排名2690/5191。工商变更将在首期款支付后60个工作日内完成。姚繁狄的交易安排仍按原协议执行。本次交易不构成重大资产重组，无需提交股东会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622878662","title":"艾迪药业（688488）披露收购控股子公司少数股东股权进展公告，3月27日股价上涨4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622878662","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622878662?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:29","pubTimestamp":1774621786,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，艾迪药业报收于16.02元，较前一交易日上涨4.98%，最新总市值为67.41亿元。近日，艾迪药业发布《关于公司收购控股子公司少数股东股权进展的公告》。公告显示，江苏艾迪药业集团股份有限公司拟以13,005.9540万元收购控股子公司南京南大药业有限责任公司少数股东华泰国信、道兴创投及姚繁狄合计持有的22.2324%股权。姚繁狄的交易安排仍按原协议执行。本次交易不构成重大资产重组，无需提交股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700050221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619108165","title":"艾迪药业最新公告：用于治疗HIV感染的多替拉韦钠片获得药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619108165","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619108165?lang=zh_cn&edition=full","pubTime":"2026-03-15 16:02","pubTimestamp":1773561722,"startTime":"0","endTime":"0","summary":"艾迪药业公告称，公司收到国家药监局核准签发的多替拉韦钠片《药品注册证书》。多替拉韦钠片仿制药获批上市，将丰富公司抗艾滋病药品种类及临床方案，与公司当前已上市的非核苷类逆转录抗HIV药物形成有效互补，提升公司核心竞争力，对公司未来的经营业绩有积极的影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260315/32069374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619911201","title":"艾迪药业：整合酶抑制剂已成为全球抗艾主流治疗方案之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2619911201","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619911201?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:12","pubTimestamp":1773400320,"startTime":"0","endTime":"0","summary":"证券日报网3月13日讯 ，艾迪药业在接受调研者提问时表示，目前，整合酶抑制剂已成为全球抗艾主流治疗方案之一。根据美国公开市场资料和相关上市公司数据，整合酶抑制剂主导美国抗HIV药物市场，销售额持续攀升。吉利德、葛兰素史克等公司旗下相关产品，美国销售额从2022年的154.87亿美元增至2025年的197.27亿美元，印证该品类在全球市场的高认可度与巨大需求空间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-13/doc-inhqvxrm4057755.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-13/doc-inhqvxrm4057755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618182245","title":"艾迪药业定增扩围背后的两难：填补巨亏窟窿，能否赌出一个未来？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618182245","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618182245?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:09","pubTimestamp":1773306540,"startTime":"0","endTime":"0","summary":"3月初，艾迪药业抛出一份上限达12.77亿元的新定增预案，而就在年初，这一数字还停留在1.85亿元。募资额的大幅膨胀，直观地揭示了这家创新药企当前的生存状态：一边是连年亏损留下的资金窟窿亟待填补，另一边是研发竞赛和商业化扩张的巨额开销必须支付。 艾迪药业面临的第一个考验，也是最直观的风险，在于其财务数据的严重背离。对于艾迪药业而言，此次定增能否顺利落地只是第一步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-03-12/doc-inhqtqkm8491648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618625522","title":"艾迪药业：3月9日高管傅和亮增持股份合计6.88万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625522","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618625522?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:01","pubTimestamp":1773057709,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月9日市场公开信息、上市公司公告及交易所披露数据整理，艾迪药业最新董监高及相关人员股份变动情况：2026年3月9日公司董事,核心技术人员傅和亮共增持公司股份6.88万股，占公司总股本为0.0164%。艾迪药业近半年内的董监高及核心技术人员增减持详情如下：艾迪药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入1775.31万，融资余额增加；融券净流入1.4万，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900030522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617687814","title":"艾迪药业：3月5日高管傅和亮增持股份合计5.31万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687814","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617687814?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:01","pubTimestamp":1772798507,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月6日市场公开信息、上市公司公告及交易所披露数据整理，艾迪药业最新董监高及相关人员股份变动情况：2026年3月5日公司董事,核心技术人员傅和亮共增持公司股份5.31万股，占公司总股本为0.0126%。艾迪药业近半年内的董监高及核心技术人员增减持详情如下：艾迪药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入1374.08万，融资余额增加；融券净流入1.4万，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600035771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779370648262,"stockEarnings":[{"period":"1week","weight":-0.0539},{"period":"1month","weight":-0.1483},{"period":"3month","weight":-0.0874},{"period":"6month","weight":0.2256},{"period":"1year","weight":0.407},{"period":"ytd","weight":-0.022}],"compareEarnings":[{"period":"1week","weight":-0.0189},{"period":"1month","weight":0.0196},{"period":"3month","weight":0.0196},{"period":"6month","weight":0.0853},{"period":"1year","weight":0.2312},{"period":"ytd","weight":0.0487}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏艾迪药业集团股份有限公司","boardCode":"AI0041","boardName":"其他制造业","stockholders":"11700人(较上一季度增加7.33%)","perCapita":"35964股","listingDate":"2020-07-20","address":"江苏省扬州市邗江区新甘泉西路69号","registeredCapital":"42078万元","survey":" 江苏艾迪药业集团股份有限公司的主营业务是抗HIV药物和人源蛋白领域药物的研发、生产及销售。公司的主要产品是乌司他丁粗品、其他人源蛋白粗品、HIV新药(艾诺韦林片)、HIV新药(艾诺米替片)、番泻叶颗粒、蜡样芽孢杆菌片、HIV诊断试剂、药品（尿激酶针剂）、低分子量肝素钠及其他。","listedPrice":13.99},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾迪药业,688488,艾迪药业股票,艾迪药业股票老虎,艾迪药业股票老虎国际,艾迪药业行情,艾迪药业股票行情,艾迪药业股价,艾迪药业股市,艾迪药业股票价格,艾迪药业股票交易,艾迪药业股票购买,艾迪药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}